Drug intelligence / Profile preview

Mioxal

Development stage: Preclinical
Lead developer: Innovation1 Biotech
Modality: Small Molecules
Administration: Oral

Overview

Mioxal is a nutraceutical complex composed of essential amino acids, natural coenzymes, and minerals. It was designed to support normal energy metabolism, improve mood, and reduce fatigue in individuals with fibromyalgia and chronic fatigue syndrome. Originally developed by Innovation1 Biotech Inc. (formerly Gridiron BioNutrients), the assets for Mioxal were acquired by Ingenius Biotech S.L. in November 2022. The product is positioned as a therapeutic tool for physicians to manage the symptoms of metabolic and fatigue-related disorders.

Brand names: Mioxal

Beyond the preview

Go deeper on Mioxal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mioxal.

Explore the full profile